Millennium Reports Promising Findings From MLN2704 Clinical Trial

Millennium Pharmaceuticals has announced final results from a Phase I clinical trial of MLN2704 in patients with advanced hormone-refractory prostate cancer. These results were presented at the 2005 Prostate Cancer Symposium taking place in Orlando, Fl.

The findings from this first in human MLN2704 single ascending dose trial indicated the molecule was well tolerated and produced sustained antitumor activity, including one patient who achieved a durable partial response in measurable disease for 11 months, as well as a sustained prostate specific antigen (PSA) decline of more than 50 percent. This patient received 14 doses prior to measurable disease progression at 47 weeks. MLN2704 is composed of a deimmunized monoclonal antibody (MLN591) directed at prostate specific membrane antigen (PSMA) conjugated to the chemotherapeutic agent DM1.